PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
6.84%
Some net income increase while VET is negative at -11.08%. John Neff would see a short-term edge over the struggling competitor.
9.05%
D&A growth well above VET's 11.64%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-697.22%
Negative yoy deferred tax while VET stands at 202.27%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
No Data
No Data available this quarter, please select a different quarter.
1315.77%
Slight usage while VET is negative at -643.19%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1315.77%
Some yoy usage while VET is negative at -643.19%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
128.43%
Well above VET's 12.69%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-3.02%
Both yoy CFO lines are negative, with VET at -54.18%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-165.51%
Both yoy lines negative, with VET at -1.46%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-59.93%
We reduce yoy other investing while VET is 110.48%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-189.76%
We reduce yoy invests while VET stands at 35.73%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
100.00%
Debt repayment growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
230.06%
We slightly raise equity while VET is negative at -7.83%. John Neff sees competitor possibly preserving share count or buying back shares.
100.86%
Buyback growth of 100.86% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.